Wuhan General Group
M2Bio Sciences, a company that develops innovative healthcare solutions through cannabis and mushroom-based sciences, with focus on psilocybin and cannabinoids, targeting drug discovery and treatment sales in anxiety, depression, ADHD.
Launch date
Employees
Market cap
AUD8.5k
Enterprise valuation
AUD9k (Public information from Sep 2024)
Share price
$0.0001 WUHN
Reno Nevada (HQ)
Date | Investors | Amount | Round |
---|---|---|---|
N/A | N/A | IPO | |
$450k | Post IPO Equity | ||
Total Funding | - |